Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen

International Journal of Cancer

Volumn 72, Issue 6, 1997, Pages 1045-1055

  Reed, Darryl S ^a,c   Romero, Pedro ^a   Rimoldi, Donata ^a   Cerottini, Jean Charles ^a   Schaack, Jerome ^b   Jongeneel, C Victor ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF COLORADO   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; HLA A1 ANTIGEN; TUMOR ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANTIGENS, NEOPLASM; BETA-GALACTOSIDASE; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; MELANOMA; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030846023     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970917)72:6<1045::AID-IJC20>3.0.CO;2-2     Document Type: Article

References (27)

1. ANDERSSON, M., PÄÄBO, S., NILSSON, T. and PETERSON, P.A., Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell, 43, 215-222 (1985).
2. BECKER, T.C., NOEL, R.J., COATS, W.S., GOMEZ, F.A., ALAM, T., GERARD, R.D. and NEWGARD, C.B., Use of recombinant adenovirus for metabolic engineering of mammalian cells. Meth. Cell Biol. 43, 161-189 (1994).
3. BEIER, D.C., COX, J.H., VINING, D.R., CRESSWELL, P. and ENGELHARD, V.H., Association of human class I MHC alleles with the adenovirus E3/19K protein. J. Immunol., 152, 3862-3872 (1994).
4. BOON, T., CEROTTINI, J.-C., VAN DEN EYNDE, B., VAN DER BRUGGEN, P. and VAN PEL, A., Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol., 12, 337-365 (1994).
5. BRASSEUR, F., and 27 OTHERS, Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer, 63, 375-380 (1995).
6. BRODSKY, F.M. and PARHAM, P., Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. J. Immunol., 128, 129-135 (1982).
7. CARREL, S., SALVI, S., HARTMANN, F. and RIMOLDI, D., Recognition of HLA-A1 by murine monoclonal antibodies. Tissue Antigens, 43, 110-115 (1994).
8. CARREL, S., SCHREYER, M., SPAGNOLI, G., CEROTTINI, J.-C. and RIMOLDI, D., Monoclonal antibodies against recombinant MAGE-1 protein identity a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells. Int. J. Cancer, 67, 417-122 (1996).
9. GOMEZMANZANO, C., FUEYO, J., KYRITSIS, A.P., STECK, P.A., ROTH, J.A., MCDONNELL, T.J., STECK, K.D., LEVIN, V.A. and YUNG, W., Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death ot human glioma cells via apoptosis. Cancer Res., 56, 694-699 (1996).
10. JAEGER, E., BERNHARD, H., ROMERO, P., RINGHOFFER, M., ARAND, M., KARBACH, J., ILSEMANN, C. HAGEDORN, M. and KNUTH, A., Generation of cytotoxic t-cell responses with synthetic melanoma-associated peptides in vivo - implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer, 66, 162-169 (1996).
11. KNOWLES, M.R. and 13 OTHERS. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med., 333, 823-831 (1995).
12. LEE, M.G., ABINA, M.A., HADDADA, H. and PERRICAUDET, M., The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther., 2, 256-262 (1995).
13. MAEURER, M.J., STORKUS, W.J., KIRKWOOD, J.M. and LOTZE, M.T., New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope based peptide vaccines. Melanoma Res., 6, 11-24 (1996).
14. MARCHAND, M. and 20 OTHERS, Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, 883-884 (1995).
15. PARHAM, P. and BRODSKY, F.M., Partial purification and some properties of BB7.2 A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3, 277-299 (1981).
16. PATARD, J.-J., BRASSEUR, F., GIL-DIEZ, F., RADVANYI, F., MARCHAND, M., FRANCOIS, P., ABI-AAD, A., VAN CANGH, P., ABBOU, C.C., CHOPIN, D. and BOON, T., Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer, 64, 60-64 (1995).
17. RANDRIANARISON, J.V. and PERRICAUDET, M., Recombinant adenoviruses as vaccines. Biologicals, 23, 145-157 (1995).
18. RIVOLTINI, L., BARRACCHINI, K.C., VIGGIANO, V. KAWAKAMI, Y., SMITH, A., MIXON, A., RESTIFO, N.P., TOPALIAN, S.L., SIMONIS, T.B., ROSENBERG, S.A. and MARINCOLA, F.M., Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res., 55, 3149-3157 (1995).
19. ROMERO, P., PANNETIER, C., HERMAN, J., JONGENEEL, C.V., CEROTTINI, J.-C. and COULIE, P., Multiple specificities in the repertoire of a melanoma patients cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. exp. Med., 182, 1019-1028 (1995).
20. ROSENBERG, S.A., YANNELLI, J.R., YANG, J.C., TOPALIAN, S.L., SCHWARTZEN-TRUBER, D.J., WEBER, J.S., PARKINSON, D.R., SEIPP, C.A., EINHORN, J.H. and WHITE, D.E., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. nat. Cancer Inst., 86, 1159-1166 (1994).
21. TOP, F.J., GROSSMAN, R.A., BARTELLONI, P.J., SEGAL, H.E., DUDDING, B.A., RUSSELL, P.K. and BUESCHER, E.L., Immunization with live types 7 and 4 adenovirus vaccines. 1. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J. infect. Dis., 124, 148-154 (1971).
22. TOSO, J., OEI, C., OSHIDARI, F., TARTAGLIA, J., PAOLETT, I.E., LYERLY, H., TALIB, S. and WEINHOLD, K., MAGE-1 specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer - characterization and antigen-specific activation. Cancer Res., 56, 16-20 (1996).
23. VAN DER BRUGGEN, P., TRAVERSARI, C, CHOMEZ, P., LURQUIN, C., DE PLAEN, E., VAN DEN EYNDE, B., KNUTH, A. and BOON, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643-1647 (1991).
24. VAN PEL, A., VAN DER BRUGGEN, P., COULIE, P.G., BRICHARD, V.G., LETHÉ, B., VAN DEN EYNDE, B., UYTTENHOVE, C., RENAULD, J.C. and BOON, T., Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145, 229-250 (1995).
25. WOLD, W., HERMISTON, T. and TOLLEFSON, A., Adenovirus proteins that subvert host defenses. Trends Microbiol., 2, 437-443 (1994).
26. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E. and WILSON, J.M., Cellular immunity to virual antigens limits El-deleted adenoviruses for gene therapy. Proc. nat. Acad. Sci. (Wash.), 91, 4407-4411 (1994).
27. ZHAI, Y., YANG, J.C., KAWAKAMI, Y., SPIESS, P., WADSWORTH, S.C., CARDOZA, L.M., COUTURE, L.A., SMITH, A.E. and ROSENBERG, S.A., Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156, 700-710 (1996).